BHCG Delivering Value Series Symposium Focuses on the Impact of Anti-Obesity Drugs

BHCG conducted its first Delivering Value Series (DVS) symposium in 2024, titled A New Frontier: The Impact of Anti-Obesity Drugs, providing insights into a new class of anti-obesity prescription drugs which can not only improve blood sugar control, but also lead to weight loss. Attendees gained an understanding about how these drugs work, their efficacy and cost and how they are or will impact benefit plans along with a broad understanding of the science of obesity and weight loss.

Presenters at the symposium included:

• Srividya Kidambi, M.D., MS, Associate Professor and Chief, Division of Endocrinology and Molecular Medicine, Froedtert & The Medical College of Wisconsin
• Panel: Kevin Mead, Obesity National Account Director, Novo Nordisk, Inc. and Paul Dempsey, National Account Manager, Novo Nordisk, Inc., (moderated by Dave Osterndorf, Centivo)
• Panel: Sara King, PharmD, Senior Manager, Clinical Account Executive, Navitus Health Solutions and Emma Holmi, PharmD, Clinical Account Executive, Navitus Health Solutions (moderated by Dave Osterndorf, Centivo).

Thank you to our educational sponsor for the symposium, Novo Nordisk. Meeting materials, including a slide representation, video recording and overview of BHCG are available for review.